Literature DB >> 29801023

Value-Based Pricing and Patient Access for Specialty Drugs.

James C Robinson1, Scott Howell2, Steven D Pearson3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29801023     DOI: 10.1001/jama.2018.5367

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.

Authors:  Yichen Zhang; Yuxuan Wei; Huangqianyu Li; Yixuan Chen; Yiran Guo; Sheng Han; Luwen Shi; Xiaodong Guan
Journal:  Pharmacoeconomics       Date:  2022-06-29       Impact factor: 4.558

2.  Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.

Authors:  Jeah Jung; Roger Feldman; Yamini Kalidindi; Thomas Riley
Journal:  JAMA Netw Open       Date:  2020-06-01

3.  Increasing the Adoption and Diffusion of a Novel Pharmacological Therapy That Is Both Mortality Reducing and Cost-Effective.

Authors:  Kristin E Bergethon; Jason H Wasfy
Journal:  J Am Heart Assoc       Date:  2019-02-05       Impact factor: 5.501

Review 4.  An Integrated Health-System Specialty Pharmacy Model for Coordinating Transitions of Care: Specialty Medication Challenges and Specialty Pharmacist Opportunities.

Authors:  Autumn D Zuckerman; Alicia Carver; Katrina Cooper; Brandon Markley; Amy Mitchell; Victoria W Reynolds; Marci Saknini; Houston Wyatt; Tara Kelley
Journal:  Pharmacy (Basel)       Date:  2019-12-03

5.  The Physician and Administrator-Reported Cost of Drug Utilization Management to Physician Practices: A Cross-Sectional Survey.

Authors:  Marie Louise Edwards; Perry T Yin; Michael Kuehn; Keith Bratti; Noam Kirson; Anupam Jena; Scott Howell
Journal:  Pharmacoecon Open       Date:  2022-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.